Metronidazole 500 mg orally twice daily for 7 days, or Metronidazole gel (0.75%), one full applicator (5 g) intravaginally, once daily for 5 days, or Clindamycin cream (2%), one full applicator (5 ...

Women's vaginal discharge is not normal if it has an unpleasant odor, itching, or pain during sexual intercourse and ...

Vaginitis Epidemiology Report 2025-2035: Drug Pipeline, Treatment, Trends, Rising Incidence & prevalence The report also provides a detailed analysis of the current vaginitis marketed drugs and ...

Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.

Vaginal microbiome-drug interactions affect antibiotic treatment for bacterial vaginosis, emphasizing the need for ...

Date 2025-06-18 04:01:02 (MENAFN - EIN Presswire) Bacterial Vaginosis Market Epidemiology Report 2025-2035: Drug Pipeline, Treatment, Trends, Rising Incidence & prevalence ...

StrategyHorizon Insights projects the market for BV treatments in the U.S. will reach $1.0 billion by 2033, propelled by increasing BV incidence, greater public health awareness, and improvements ...

-- BV Market Projected to Reach $1.0 Billion in the U.S. by 2033 -- -- BV Affects 21 Million U.S. Women; As many as 50% Experience Recurrent BV Within Six Months of Treatment -- SAN DIEGO, June 11 ...

It is FDA-approved for the treatment of two sexual health diseases: Bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and Trichomonas vaginalis, a common ...

CLINICALLY PROVEN pH BALANCE FOR BV TREATMENT - In a study involving 48 women, 83% experienced significant improvements in recurrent BV symptoms like vaginal odor, pH balance, itching, and ...

Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for recurrent bacterial vaginosis (BV) presented at the 2025 ...